# Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform

> **NCT02196207** · PHASE3 · WITHDRAWN · sponsor: **Margaret Ragni**

## Conditions studied

- Severe Hemophilia A

## Interventions

- **DRUG:** Eloctate Prophylaxis
- **DRUG:** Emicizumab Prophylaxis
- **DRUG:** Eloctate ITI plus Emicizumab
- **DRUG:** Eloctate ITI

## Key facts

- **NCT ID:** NCT02196207
- **Lead sponsor:** Margaret Ragni
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-08
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The trial was revised to be two protocols, one Prevention, one Eradication Trials.
- **Last updated:** 2019-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02196207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02196207, "Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02196207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*